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Abstract
Background: Papillary thyroid carcinoma (PTC) frequently presents as multiple tumour-foci within a single thyroid gland or
pluriform, with synchronous tumours comprising different histological variants, raising questions regarding its clonality. Among
the genetic aberrations described in PTC, the BRAF V600E mutation and ret/PTC activation occur most commonly. Several studies
have investigated the genetic alteration status of multifocal thyroid tumours, with discordant results.
To address the question of clonality this study examined disparate geographical and morphological areas from a single PTC
(classic PTC, insular and anaplastic foci, and tumour cells adjacent to vascular invasion and lymphocytic infiltrate) for the
presence of ret/PTC 1 or BRAF mutations. Moreover, we wanted to investigate the consistency of miRNA signatures within
disparate areas of a tumour, and geographical data was further correlated with expression profiles of 330 different miRNAs.
Putative miRNA gene targets were predicted for differentially regulated miRNAs and immunohistochemistry was performed on
tissue sections in an effort to investigate phenotypic variations in microvascular density (MVD), and cytokeratin and p53 protein
expression levels.
Results: All of the morphological areas proved negative for ret/PTC 1 rearrangement. Two distinct foci with classic morphology
harboured the BRAF mutation. All other regions, including the insular and anaplastic areas were negative for the mutation.
MiRNA profiles were found to distinguish tumours containing the BRAF mutation from the other tumour types, and to
differentiate between the more aggressive insular & anaplastic tumours, and the classic variant. Our data corroborated miRNAs
previously discovered in this carcinoma, and additional miRNAs linked to various processes involved in tumour growth and
proliferation.
Conclusion: The initial genetic alteration analysis indicated that pluriform PTC did not necessarily evolve from classic PTC
progenitor foci. Analysis of miRNA profiles however provided an interesting variation on the clonality question. While
hierarchical clustering analysis of miRNA expression supported the hypothesis that discrete areas did not evolve from clonal
expansion of tumour cells, it did not exclude the possibility of independent mutational events suggesting both phenomena might
occur simultaneously within a tumour to enhance cancer progression in geographical micro-environments within a tumour.
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Background
Thyroid cancer is the most common endocrine malig-
nancy and accounts for the majority of endocrine cancer
deaths each year [1]. Carcinomas of the thyroid comprise
a heterogeneous group of neoplasms with distinctive clin-
ical and pathological characteristics. Most thyroid cancers
originate from the follicular cell epithelium. The majority
of tumours are designated as papillary thyroid cancer
(PTC) and are well differentiated, indolent and are associ-
ated with good prospects of survival. Undifferentiated or
anaplastic carcinomas, however, are very aggressive with
survival rates of less than one year in most instances [2].
Thyroid cancer harbours several highly prevalent genetic
alterations including ret/PTC rearrangements, Ras muta-
tions, and BRAF V600E point mutations [3]. There have
been intriguing associations between the morphology of
PTC and specific molecular findings. In the past our group
and others have noted an association between classic PTC
morphology and the BRAF V600E mutation and between
variant morphology and ret rearrangements particularly
ret/PTC 3 [4,5]. Similarly ret/PTC 3 appears to strongly cor-
relate with the solid/follicular variant seen commonly in
children exposed to Chernobyl fallout [6].
PTC frequently presents as multiple tumour-foci within a
single thyroid gland. In addition, a significant proportion
of PTC are also pluriform, with synchronous tumours
comprising of different histological variants. These PTC
foci may either arise from intrathyroidal metastasis of a
clonal population of cells or as a consequence of multiple
tumours arising independently. Several studies have been
performed using various techniques in an effort to eluci-
date whether most poorly differentiated anaplastic carci-
nomas develop through a multi step carcinogenesis
process from the well differentiated thyroid cancer sub-
types, or if they arise independently [7-15]. Among
genetic aberrations described in PTC, the BRAF  V600E
mutation and ret/PTC activation occur most commonly.
Most of the studies thus far have focused on investigating
the genetic alterations present in the different foci in an
effort to determine their origin and potential clonality.
Unfortunately these studies have produced conflicting
results to date and no consensus has been reached. In
order to further advance this research, examination of the
regulatory environment of the thyroid along with genetic
alteration analysis may prove beneficial.
MicroRNAs (miRNA) are a recently discovered family of
short non-protein-coding RNAs with diverse functions,
including regulation of cellular differentiation, prolifera-
tion and apoptosis [16]. These small non-coding RNAs
constitute a novel class of gene regulators that function by
negatively regulating gene expression by targeting mRNAs
for cleavage or translational repression. To date, 695
human miRNAs have been identified [17], however, evi-
dence suggests the total number of human miRNAs may
be much larger. Studies have indicated that different pop-
ulations of miRNAs are expressed in cancer and normal
tissues with general down regulation of miRNAs in
tumours, suggesting that tumours may each have a dis-
crete "miRNA signature" [18]. MiRNAs are also thought to
be capable of acting as both tumour suppressors and
oncogenes. This differential expression of miRNAs
between malignant and normal tissues and between dif-
ferent types of tumour may indicate that miRNAs are
determinants of clinical diagnostic and prognostic signif-
icance. Recent studies in miRNA expression in PTC have
found an aberrant miRNA expression profile in PTCs
compared with normal thyroid tissues [19-21].
The origin of multifocal thyroid lesions is potentially an
important issue in patient treatment. In fact, multicentric
cancer has been associated with local and distant metas-
tases, mortality, and tumour recurrence [22]. If multiple
foci are found to be clonal in origin due to the intraglan-
dular metastases of a single tumour, it may indicate an
increase in the aggressiveness of the cancer & therefore it
may be more likely to further metastasize into other tis-
sue. If this is discovered a more aggressive treatment
approach could be required.
To expand on the question of clonality, the objective of
this study was to examine disparate geographical and
morphological areas from a single PTC for the presence of
ret/PTC 1 or BRAF mutations and correlate it with miRNA
expression profiles. A multicentric case containing classic
PTC, insular and anaplastic foci, and areas of lymphocytic
infiltrate and vascular invasion was selected for analysis.
The expression of 330 miRNAs was examined using a
recently developed technique, which uses stem loop prim-
ers for reverse transcription followed by real time Taq-
Man® PCR [23].
Hierarchical clustering analysis of the profiles produced
was carried out, along with miRNA gene target prediction.
Immunohistochemistry was also performed on tissue sec-
tions in an effort to investigate phenotypic variations in
microvascular density (MVD), and cytokeratin and p53
protein expression levels. The varying miRNA profiles
within different foci of a single tumour illustrate how a
tumour's microenvironment can affect regulatory proc-
esses underpinning carcinogenesis, and highlight a caveat
that ought to be observed in the search for the discovery
of future cancer biomarker signatures, particularly in the
context of multifocal tumours. Many miRNA studies to
date have highlighted characteristic 'signatures' that asso-
ciate with particular tumours/phenotypes. In this study
we demonstrate that regulatory processes engendered by
non-coding RNAs are more subtle and signatures can varyMolecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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within individual areas of a single tumour. Laser Micro-
dissection ensured that the cells interrogated were homog-
enous and follicular epithelial in origin, nonetheless their
miRNA profiles varied depending on the specific micro-
environment from which they were harvested.
Methods
Tissue sample
A single archival case of formalin fixed, paraffin-embedded
(FFPE) multifocal thyroid tumour was chosen for this analy-
sis. Eight areas were chosen for examination: 1 normal thy-
roid, 2 classic PTC, 1 insular, 2 anaplastic thyroid carcinomas,
1 area surrounding lymphocytic infiltrate, and 1 surrounding
vascular invasion. Haematoxylin and eosin (H&E) sections
were reviewed by a histopathologist (RF) and classified
according to a recognized system [24]. Corresponding paraf-
fin blocks were then collected from the archives of St. James
Hospital. Ethical approval for this study was granted by the
SJH/AMNCH Research Ethics Committee.
Laser capture microdissection
6 μm sections were cut using a microtome (Microm HM
325, Medical Supply Co. Ltd, Ireland) from each paraffin
block, mounted on uncharged slides, dewaxed and H&E
stained (Tissue-Tek DRS 2000 Autostainer, Sakura, CA,
USA). Pure populations of thyrocytes were obtained from
each section by laser capture microdissection using the
PixCell II System (Acturus Engineering Inc., CA, USA).
Laser capture microdissection produces low yet accurate
yields of RNA & DNA (yields in the range of 1.7–9 ng/μl
of RNA & 3.2–8.8 ng/μl of DNA were achieved in this
study). Cells were captured according to a standard proto-
col: laser spot size = 15 μm, pulse power = 25 mW, pulse
width = 1.5 ms, threshold voltage = 285 MV. The total
number of pulses in each case was approximately 700
(range = 500–1200). After microdissection the Capsures®
(Capsuret Macro LCM caps, LCM 0201, Techno-Path Ltd,
Ireland) containing the homogenous cell populations
were placed in a sterile microcentrifuge tube ready for
RNA & DNA extraction.
Nucleic acid extraction
DNA & RNA were extracted using the RecoverAll™ Total
Nucleic Acid Isolation, Optimized for FFPE Samples Kit
(Ambion, Texas, USA), according to the manufacturers'
instructions, with the exception of the tissue deparaffini-
zation step of the protocol as the sections had been depar-
affinised during the H&E staining. Purified RNA & DNA
were eluted in 60 μl volumes and the nanogram concen-
tration per microlitre was verified using a Nanodrop spec-
trophotometer (ND-1000, Labtech International, UK).
TaqMan® expression analysis
BRAF V600E mutation detection
TaqMan® SNP detection was used for BRAF V600E muta-
tion detection as previously described [4]. Primers and
probes used in this experiment were designed and used to
the manufacturer's recommendations. The primers/
probes used were as follows: 5' CAT GAA GAC CTC ACA
GTA AAA ATA GGT GAT 3' [BRAF-F], 5' GGA TCC AGA
CAA CTG TTC AAA CTG A 3' [BRAF-R], VIC-5' CCA TCG
AGA TTT CAC TGT AG 3' [BRAF-PWT], and FAM-5' CCA
TCG AGA TTT CTC TGT AG 3' [BRAF-PMUT]. Amplifica-
tion and analysis was performed using an ABI Prism 7900
HT Sequence Detection System (Applied Biosystems, CA,
USA) for 40 cycles (92°C for 15 sec, 60°C for 1 min).
Ret/PTC1 rearrangement detection
TaqMan® RT-PCR was used for ret/PTC 1 rearrangement
detection. Primers and probes used in this experiment
were designed and used according to the Applied Biosys-
tems (Foster City, CA, USA) Assays-by-Design SM service.
Amplification and analysis was performed on an ABI
Prism 7900 HT Sequence Detection System (Applied Bio-
systems, CA, USA) (48°C for 30 min then 92°C for 15 sec,
60°C for 1 min × 40 cycles).
MiRNA analysis
Multiplexing stem-loop RT-PCR with mir-16 as an endog-
enous control was used to analyse miRNA profiles as pre-
viously described [25]. Briefly, the process involves three
steps. Steps 1 and 2 are multiplexed reactions with 330
sets of primers for 330 miRNAs. Step 1 reverse transcribes
all the miRNAs in a single reaction and then step 2 PCR
amplifies the cDNA products to provide enough sample
for step 3. Step 3 is done as simultaneous, individual sin-
gleplex TaqMan® reactions in 96-well reaction plates to
monitor the abundance of each miRNA after the multi-
plexed RT-PCRs. Sequences for primers and probes will be
provided by the authors upon request. As previously,
amplification was performed using an ABI Prism 7900 HT
Sequence Detection System (Applied Biosystems, CA,
USA).
Data analysis
ΔΔCT studies were performed on the miRNA data using
the SDS 2.1 software (Applied Biosystems, CA, USA). The
studies were then exported to the Microsoft® Office Excel®
2003 software (Microsoft Corporation, WA, USA) for fur-
ther analysis. The primary means of identifying differen-
tially expressed miRNAs was based on fold change.
MiRNAs were considered differentially expressed between
tumour areas if they possessed fold changes >2 or <0.5.
Hierarchical clustering analysis was performed using the
Spotfire programme. Clustering analysis was performed
using WPGMA and similarity between samples was
assessed by correlation analysis. Up & down regulated
miRNAs were entered into the three-way intersection in
the miRGen database to search for putative miRNA target
genes [26]: http://www.diana.pcbi.upenn.edu/miR
Gen.html). Gene ontology analysis of the putative target
gene lists was then performed using the PANTHER data-Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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base http://www.pantherdb.org/. This enabled the identi-
fication of significantly over and under represented
pathways in the gene lists.
Immunohistochemistry
6 μm sections were cut from the archived blocks, depar-
affinised, and dehydrated. Sections underwent heat
induced epitope retrieval using Trilogy (CellMarque,
Greenwood, AR). Immunohistochemical staining, using
Monoclonal Mouse Anti-Human cytokeratin (DakoCyto-
mation, Copenhagen, Denmark), CD34 (Serotec, Oxford,
UK), and p53 (Novocastra, Newcastle upon Tyne, UK),
was performed on the Nexes immunostainer using a
strepavidin peroxidise procedure. Antigen-bound primary
antibody was detected using strepavidin-biotin immu-
noperoxidase complex (Ventana i-view kit, Ventana Med-
ical Systems). Slides were examined blind by a
histopathologist (RF) and classified according to a recog-
nized system [27].
Results
Genetic alteration status
TaqMan® RT-PCR was used to detect the presence of ret/
PTC 1 rearrangement in follicular epithelial cells dissected
from each of the eight designated areas (1 normal thyroid,
2 classic PTC, 1 insular, 2 anaplastic thyroid carcinomas,
1 area surrounding lymphocytic infiltrate, and 1 sur-
rounding vascular invasion). RNA from the TPC1 cell line
was used as a positive control. All areas proved negative
for ret/PTC 1 rearrangement.
TaqMan® SNP detection was used to detect the presence of
the BRAF mutation. This assay acts as its own endogenous
control as the wild type allele will be detected in the
absence of the mutant. The two foci with classic morphol-
ogy harboured the BRAF  mutation. All other tumour
areas, including the insular and anaplastic areas were neg-
ative for the mutation (Figure 1). This result indicates that
the anaplastic lesions may not have evolved from progen-
itor classic PTC foci.
Regulatory environment analysis
Geographical patterns in miRNA expression
Expression levels of 330 miRNAs were analysed in the
eight thyroid geographical regions (Figure 2). The ΔΔCT
method [28] was used to calculate the fold change of
miRNA expression between tumour areas, and miRNAs
were considered differentially expressed if they possessed
fold changes >2 or <0.5. Cells from the area of normal thy-
roid epithelium were utilised to calibrate the study, and
mir-16 was used as an endogenous control.
Figure 2 illustrates the miRNA expression profiles in the
different tumour areas. It may be noted from this figure
that expression of miRNAs across the tumour areas
appears to be non-homogenous. Of the 330 miRNAs, 225
(68%) were expressed in the tissues studied. All of the can-
cer areas (classic PTC, insular, and anaplastic cancer)
showed a general down-regulation in miRNA expression
compared to normal thyroid tissue (avg 53.9%) which is
the general trend observed when comparing miRNAs in
cancer tissues to normal tissue [18]. Interestingly, the cells
surrounding the areas of lymphocytic infiltrate and vascu-
lar invasion showed a marginal increase in miRNA expres-
sion compared to normal thyroid epithelium (avg
53.4%). These cells were captured from an area of ana-
plastic carcinoma. Perhaps the up-regulation of miRNAs
surrounding these areas may enable the down-regulation
of gene expression to facilitate angiogenesis and metasta-
sis in this aggressive cancer and assist in its evasion of the
immune system (See Additional file 1 for miRNA RQ val-
ues).
Table 1 shows the top five up and down regulated miR-
NAs in each tumour area compared to normal thyroid tis-
sue. This table, in contrast with figure 2, emphasizes the
similarities that can be noted between the profiles with
mir-221 appearing up-regulated in all tumour areas, and
mir-124a and mir-328 appearing prevalently down-regu-
lated in tumour areas. An inevitable element of similarity
must be expected in the profiles of these tumour areas as
they originate from a single thyroid specimen.
TaqMan® SNP assays for BRAF V600E mutation detection Figure 1
TaqMan® SNP assays for BRAF V600E mutation 
detection. DNA from the TPC1, BC-PAP, and K-2 cell lines 
was used for positive control purposes. TPC1 contains the 
wild type BRAF allele, K-2 is heterozygous for the mutant 
allele, and BC-PAP is homozygous for the mutant allele. The 
figure shows clustering of the samples into 3 distinct groups 
depending on their respective levels of VIC/FAM fluores-
cence: homozygous T1799A mutation (l), homozygous 
wild-type/normal (l) and heterozygous T1799 mutation (l). 
Negative controls and undetermined samples are also dis-
played (×). The two classic PTC tumour areas are the only 
ones that exhibit the BRAF mutation.Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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Heat map of miRNA expression Figure 2
Heat map of miRNA expression. Each miRNA listed was considered differentially expressed between tumour areas if they 
possessed fold changes >2 or <0.5.Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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Hierarchical clustering analysis was then performed on
the miRNA data to further investigate the potential simi-
larities and differences between the miRNA profiles (Fig-
ure 3). The analysis revealed two main clusters, with one
cluster dividing into two sub-groups. The normal thyroid
epithelium forms one of the main clusters and groups sep-
arately to all of the cancer areas. The insular cancer and
anaplastic carcinoma 2 areas form one sub-group, and the
other tumour areas form the other sub-group. As illus-
trated from figure 3b, the insular and anaplastic carci-
noma 2 samples were excised from regions of close
proximity, and the lymphocytic infiltrate, vascular inva-
sion, and anaplastic carcinoma 1 areas were harvested
from the same geographical region. This clustering of
miRNA profiles corresponding to the geographical posi-
tion of the cells suggests that the location of the cancer
foci within the tumour may influence the miRNA profiles.
However as mentioned previously, an element of similar-
ity in profiles must be anticipated in cells adjacent to each
other.
In juxtaposition to the geographical clustering of cellular
areas, the classic PTC 2 miRNAs sub-group with the other
PTC area, separating it from the other foci from the same
tissue section (insular and anaplastic carcinoma 2). This,
along with possession of the BRAF  mutation, points
towards the similarity of the classic PTC genetic profiles.
However the two anaplastic areas divide into separate
sub-groups. This raises the question as to why the cancer
foci are behaving differently and not grouping together.
The grouping of the two classic PTC foci which both con-
tain the BRAF mutation indicates that their genetic pro-
files are similar and may suggest that these two foci may
be clonal in origin and have originated from the same
mutational event or cascade. However, the anaplastic car-
cinomas separate into the two sub-groups within the can-
cer cluster perhaps indicating that these cancers may have
arisen independently. Therefore it may not be a question
as to whether multifocal tumours arise due to the clonal
metastasis of tumour cells or of independent mutational
events, but perhaps both phenomena can occur simulta-
neously within the one tumour to enhance cancer pro-
gression.
Expression of miRNAs in thyroid tumours containing BRAF mutation
Along with looking at the overall geographical trends of
miRNA expression in a multifocal tumour, this data ena-
bled us to view the tumour categorically and explore spe-
cific aims and questions. Therefore we consequently
looked at distinguishing the BRAF containing PTC foci
from the other cancer areas. A number of miRNAs were
found to be both up and down regulated in the PTC areas
in comparison to all the others (Table 2). These profiles
indicate that PTC can be further distinguished from the
other tumour areas. Furthermore, several of these miRNAs
correspond with miRNAs published in thyroid cancer-
related papers, and papers relating miRNAs to the
tumourigenesis process from our group and others. For
instance mir-222 [19,20], mir-106a [29,30], mir-26a
[19,29], and mir-34c [31-33].
Expression of miRNAs in aggressive thyroid tumours
It is interesting to further investigate and attempt to distin-
guish between the anaplastic and insular tumours as they
are more aggressive than the usually indolent classic PTC.
Several miRNAs were found to be both up and down reg-
ulated in the anaplastic areas compared to the insular
area. Table 3 shows a selection of the miRNAs discovered.
Table 1: Five most up and down regulated miRNAs in each tumour area compared to normal thyroid epithelium.
Up-regulated miRNAs
Classic PTC Insular Carcinoma Anaplastic Carcinoma Lymphocytic Infiltrate Vascular Invasion
mir-221 mir-221 mir-221 mir-221 mir-221
mir-324-5p mir-486 mir-205 mir-205 let7e
mir-93 mir-205 mir-324-5p mir-378 mir-412
mir-182* let7e mir-486 let7e mir-15a
mir-378 mir-320 mir-93 mir-15a mir-497
Down-regulated miRNAs
Classic PTC Insular Carcinoma Anaplastic Carcinoma Lymphocytic Infiltrate Vascular Invasion
mir-124a mir-124a mir-328 mir-328 mir-328
mir-192 mir-520e mir-149 mir-124a mir-423
mir-UL148D-1 mir-345 mir-520e mir-192 mir-518a-2*
mir-let-7g mir-7 mir-375 mir-152 mir-124a
mir-let7f mir-140 mir-124a mir-127 mir-152Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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Hierarchical Clustering of miRNA profiles Figure 3
Hierarchical Clustering of miRNA profiles. (A) Hierarchical clustering diagram of the miRNA profiles of the thyroid 
tumour areas. (B) Images illustrating the geographical location of the tumour foci in respect to each other.Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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It can be noted that the three miRNAs most up-regulated
in anaplastic carcinoma compared to the insular tumour
have extremely high RQ values (15668.58, 2326.54,
474.51). One might think that these high values could be
explained if those miRNAs; mir-140, mir-345, mir-7
respectively, are not expressed in the calibrator sample,
however they are expressed in that sample so these
extreme values cannot be attributed to that. The three
miRNAs most down-regulated in anaplastic carcinoma
also have extreme RQ values. In this study miRNA expres-
sion was evaluated through relative quantification; there-
fore these values may result from low expression levels of
those miRNAs in the calibrator sample, or very high
expression in the tumour areas.
Some of these differentially regulated miRNAs in the ana-
plastic carcinomas have also been noted in papers pub-
lished by our group and others, for instance mir-221
[19,20], mir-200a [20,31,32], mir-155 [29,30,32,34], and
mir-125b [20,29,31].
MiRNAs; biomarkers or crucial biological mediators?
There are currently two main schools of thought as to the
utility of these small RNA gene regulators in the advance-
ment of disease treatment. The first, and most common
up to now, being to focus on data such as that above and
utilize these RNAs as potential new biomarkers. This has
resulted in the publishing of numerous papers proposing
potential miRNA cancer signatures with the view to
improve diagnosis and early detection [19-21].
The other approach is to view these RNAs as the key to a
plethora of knowledge regarding the functioning of cells
and the body in both normal and disease states. This
involves elucidating the gene targets of the miRNAs and
therefore their functions and influence in the cell. MiR-
NAs are already thought to possess oncogenic and tumour
suppressor capabilities, however accurately identifying
biologically relevant targets that are regulated by individ-
ual miRNAs is currently the predominant challenge in this
area of research. This task is further complicated by the
fact that each miRNA can potentially regulate many
mRNA targets and also each mRNA can be regulated by
several miRNAs.
To further explore this aspect of miRNA functionality we
attempted to investigate potential targets for the miRNAs
listed in tables 2 &3. Several publicly available databases
exist for prediction of miRNA target genes. The miRGen
database was used in this analysis as it allows the produc-
tion of lists of gene targets common to three target predic-
tion databases (miRanda, PICTAR, & TARGETSCAN)
allowing for increased confidence in the target lists pro-
duced. The miRGen putative gene target lists were then
entered into the PANTHER database in order to identify
significantly over and under represented pathways. The
binomial statistic was used to estimate this [35]. One
Table 2: Differentially expressed miRNAs in classic PTC tumour 
areas v all others. 
Up-regulated miRNAs Down-regulated miRNAs
mir-191* mir-106b
mir-146b mir-451
mir-US33-1 mir-26a
mir-151 mir-199a*
mir-193b mir-193a
mir-222 mir-34c
mir-518a-2* mir-UL22A-1
mir-106a mir-492
mir-296 mir-148b
mir-197 mir-UL112-1
mir-328 mir-500
mir-331 mir-UL148D-1
mir-423 mir-let7f
mir-146a
Other areas include insular and anaplastic, and thyrocytes 
surrounding lymphocytic infiltrate and vascular invasion.
Table 3: Differentially expressed miRNAs in anaplastic tumour areas v insular. 
miRNAs Up-regulated in Anaplastic RQ miRNAs Down-regulated in Anaplastic RQ
mir-140 15668.58 mir-328 0.000003
mir-345 2326.54 mir-375 0.00001
mir-7 474.51 mir-149 0.00002
Mir-124a 23.18 mir-148b 0.067
mir-221 18.07 mir-150 0.170
mir-192 16.39 mir-27b 0.253
mir-99a 12.66 mir-155 0.302
mir-127 8.80 mir-30a-5p 0.356
Mir-let7a 6.30 mir-125b 0.400
mir-let7f 3.75 mir-30d 0.430
Mir-200a 2.50 mir-15b 0.456
The table also shows the fold change in expression.Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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could predict that up-regulated miRNAs would down-reg-
ulate their target genes which would in turn down-regu-
late the pathways over represented in that list. From this
one could also infer that down-regulated miRNAs would
result in an up-regulation of their target genes and path-
ways. Pathways such as cytoskeletal regulation by Rho
GTPases (p = 0.01) and angiogenesis (p = 0.00006) were
significantly over-represented in the putative target lists
correlating to miRNAs down-regulated in PTC compared
to all other areas, and Wnt (p = 0.00009) and angiogen-
esis (p = 0.003) pathways were significantly over-repre-
sented in the putative target lists correlating to miRNAs
down-regulated in anaplastic cancer compared to insular
cancer (thus inferring their possible up-regulation at the
transcriptome level).
Although these are predicted results, they may lead us in
the right direction in revealing the biological functioning
of these miRNAs. Therefore, in an effort to explore the
behaviour of some cellular processes across different areas
of morphology in a multifocal tumour, we performed
some immunohistochemistry on our tissue sections (Fig-
ure 4). CD34 was analysed in an effort to assess microvas-
cular density (MVD), cytokeratin to stain epithelial cells
and view differentiation status, and p53 as it is commonly
mutated in this cancer. Morphological assessment and
evaluation of staining intensity may hint at performance
of some of the pathways mentioned previously such as
angiogenesis and cytoskeletal regulation and wnt signal-
ing.
MVD was marginally increased in anaplastic cancer (n =
197) compared to PTC (n = 131). There are varying
reports on the MVD in different thyroid cancers; some
show that reduced MVD in poorly differentiated cancer is
associated with poor differentiation and worse prognosis,
and others demonstrate increased risk of recurrence and
shorter disease-free survival with more vascular PTCs [36].
Strong intensity of staining in a high number of cells was
observed with the cytokeratin giving an immuno score of
7 for all areas. However there was no staining observed in
the squamoid and spindled/sarcomatoid components of
the anaplastic cancer illustrating the dedifferentiation of
these cells. Finally, there was a marginal increase in p53
between the anaplastic areas (immuno score = 4) com-
pared to the classic PTC areas (immuno score = 3). An
activating mutation in the p53 gene could explain this
increase in expression as mutated p53 is often found in
anaplastic carcinoma [37].
Discussion
The objective of this study was to examine the question of
clonality in multicentric PTC through correlating the
miRNA profiles and genetic alteration status of eight
tumour areas in a case of multifocal thyroid cancer.
All of the tumour areas examined (one area of normal thy-
roid, two of classic PTC, one insular, two anaplastic thy-
roid carcinomas, and thyrocytes surrounding an area of
lymphocytic infiltrate and vascular invasion) proved neg-
ative for ret/PTC 1 rearrangement. The two foci with clas-
sic morphology harboured the BRAF mutation. All other
tumour areas, including the insular and anaplastic were
negative for the mutation. This result suggests that the
tumours in this thyroid arose independently and not as a
result of intrathyroidal metastasis of a clonal population
of cells. This outcome also agrees with previous reports
supporting this theory. Park [11] and Giannini [8] both
studied BRAF mutation rate on 61 and 69 patients respec-
tively and their results suggested 39.3% and 40% of the
multifocal tumours may have arisen independently. Sugg
and colleagues [15] proposed that the majority of the
tumours they tested arose independently by showing dis-
tinct patterns of ret/PTC rearrangement in multifocal PTC.
Shattuck and colleagues [13] examined BRAF by utilising
X-chromosome inactivation on samples from 10 patients
and reported discordant genetic patterns in 50% of the
multicentric PTC. However, McCarthy [10] also used X-
chromosome inactivation and produced results that sup-
port the theory of intrathyroidal metastasis. This discord-
ance of conclusions resulting from genetic alteration
analysis illustrates that additional analysis would be ben-
eficial in unravelling the tumourigenesis process.
Subsequent to revealing the differential BRAF status of the
tumour areas, the study of the profiles of 330 miRNAs in
the areas provided further insight into multifocal cancer.
These miRNA profiles of the different tumour areas high-
lighted the fact that both similarities and differences could
be found between the different foci. The heat-map in fig-
ure 2 illustrated the apparent non-homogenous nature of
the profiles, however when the most highly up and down
regulated miRNAs from each area are viewed (Table 1),
the similarities become more evident. This is an encourag-
ing observation as one would expect similarities in the
profiles of cells located close to each other, however dif-
ferences in the profiles of different morphological variants
would also be expected, as shown by Nikiforova and col-
leagues [21]. The down-regulation of miRNAs in the can-
cer areas compared to normal thyroid epithelium follows
trends found generally when comparing cancers to nor-
mal tissue [18]. The up-regulation of miRNAs in thyro-
cytes surrounding areas of lymphocytic infiltrate and
vascular invasion is an interesting result as the differential
regulation in miRNA and in turn gene expression may aid
the progression of the cancer.
The hierarchical clustering analysis performed on the
miRNA profiles unearths some exciting findings (Figure
3). The normal and cancerous tissue cluster separately and
there is a further sub-grouping within the cancer cluster.Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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H&E & immunohistochemistry staining of thyroid sections Figure 4
H&E & immunohistochemistry staining of thyroid sections. (A) H&E stained sections of normal thyroid, classic PTC, 
anaplastic thyroid cancer, and insular carcinoma. (B) Immunohistochemical staining for CD34 in normal, PTC, and anaplastic 
sections. (C) Immunohistochemical staining for p53 in normal, PTC, and anaplastic sections. (D) Immunohistochemical staining 
for cytokeratin in normal thyroid, and in an area showing classic PTC and anaplastic cancer areas.Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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Initial examination of the figure may suggest that the
tumour areas group together depending on their geo-
graphical position within the thyroid. The sites of the dif-
ferent tumour areas captured within the thyroid section
can be viewed in figure 3b, and compared to the two sub-
groups in which they fall in figure 3a. From this one can
see that the anaplastic carcinoma 1, lymphocytic infiltrate,
and vascular invasion all fall into the same sub-group, and
the insular and anaplastic carcinoma 2 areas also sub-
group together. However the classic PTC 2 area groups
away from the other tumour foci that are close to it and
aligns itself with the other PTC area. This may indicate
that these two foci, which both contain the BRAF muta-
tion, possess similar genetic profiles and may suggest that
they are clonal in origin and have originated from the
same mutational event. However, the anaplastic carcino-
mas separate into the two sub-groups within the cancer
cluster perhaps indicating that these cancers may have
arisen independently. Therefore one might speculate that
it may not be a question as to whether multifocal tumours
arise due to the clonal metastasis of tumour cells or of
independently mutational events, but perhaps both phe-
nomena can occur simultaneously within the one tumour
to enhance cancer progression.
The ability of the miRNA profiles to distinguish the classic
PTC foci from all other cancer areas, and the two more
aggressive types of cancer from each other (Tables 2 &3)
enforces the concept of divergent miRNA profiles within
disparate foci of a multifocal tumour. Previous studies
involving miRNA expression profiling have compared
tumour to normal tissue to determine the differentially
regulated miRNAs and in turn potential biomarkers [18].
Due to the many types of thyroid cancer, miRNA profiles
have been examined in several different thyroid tumours
[21]. However no study has investigated miRNA expres-
sion within a multifocal tumour. The varying miRNA pro-
files in the different foci of this tumour highlight a caveat
that ought to be observed in the search for the discovery
of future cancer biomarker signatures, particularly in the
context of multifocal tumours.
This body of work also invokes a debate as to the practical
uses of this emerging technology. Are these small RNAs to
be considered solely as biomarkers as discussed above, or
should we delve deeper into the functions of these regula-
tors to enhance our understanding of disease processes?
For instance, do the miRNAs respond to the cellular
changes observed when a normal cell transforms into a
cancer cell, or are they intrinsic mediators in this transfor-
mation. It has been previously suggested that miRNAs
may possess oncogenic or tumour suppressor roles in the
cell. For research in this field to progress, advancements
must be made in the discovery of the gene targets of the
miRNAs. For this reason we endeavoured to predict the
gene targets of some of the miRNAs found to be differen-
tially regulated in this study. These predicted results gen-
erated some biologically plausible pathways that may be
influenced by miRNAs in the development of this cancer.
Pathways such as angiogenesis and Wnt signalling are par-
ticularly relevant when considering the biology of this
cancer due to their previous associations with this disease.
Components of the Wnt signalling pathway such as β-cat-
enin and APC have been found to be mutated in many
cancers including thyroid cancer [38]. The pathway can be
hyperactivated due to DNA methylation or specific muta-
tions resulting in the stimulation of cancer progression via
the up-regulation of multiple genes involved in cell cycle
progression, invasion, motility, and differentiation [39].
Aberrant activation of the Wnt pathway has been linked to
the dedifferentiation of thyroid cells, a process universally
observed with anaplastic thyroid cancer [40]. This path-
way could have a role in the dysregulation of the cytoskel-
eton through the disruption of the cadherin-catenin
complex comprised of e-cadherin, β-catenin, and α-cat-
enin. Disruption or loss of the complex plays a prominent
role in cancer and leads to loss of cell-cell adhesion,
cytoskeletal remodelling, and increased migration in a
process related to epithelial to mesencymal transition
(EMT). EMT is a common occurrence in cancer progres-
sion and plays an important role in metastasis [41]. The
majority of carcinomas (including thyroid cancer) lose e-
cadherin mediated cell-cell adhesion. Smyth and col-
leagues [42] investigated e-cadherin mRNA expression in
various thyroid tissue types and found a decrease in
expression levels with decreasing differentiation. The up-
regulation of the Wnt signalling pathway observed in this
study and the reported loss of e-cadherin expression in
anaplastic cancer could culminate in the disruption of the
cadherin-catenin complex may be an important factor in
the dedifferentiation and malignancy of this cancer.
Angiogenesis is also a prevalent feature in thyroid cancer,
and one of the hallmarks of cancer. Mutation of the
tumour suppressor p53 is commonly found in anaplastic
cancer and was observed here (Figure 4). Hassan & col-
leagues [43] showed that secretion of VEGF was decreased
by 34% in undifferentiated thyroid cancer cells in which
mutated p53 has been knocked down; implicating this
protein in angiogenesis. There have also been studies
showing the ability of exogenous wild type p53 to
increase chemosensitivity in ATC cell lines. It has been
suggested that the combination of chemotherapy with
wild type p53 gene therapy may be efficacious in treating
ATC [37]. Therefore, although the results of gene targets
analysis are speculative at this stage, they may provide
insight into miRNAs' role in the mechanisms of cancer
progression and provide inspiration for further research.Molecular Cancer 2008, 7:89 http://www.molecular-cancer.com/content/7/1/89
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Conclusion
The genetic analysis performed on the multifocal thyroid
tumour areas consisting of divergent morphologies indi-
cated that the insular and anaplastic tumours did not arise
from PTC progenitor foci. However, due to the discord-
ance in conclusions in other studies examining this issue,
the miRNA profiles of the tumour areas were examined in
an effort to shed further light on the tumourigenesis proc-
ess. This analysis provided an interesting interpretation to
the answer of the clonality question. Similarities were
seen among the tumour areas (which must be anticipated
due to the close proximity of the foci) but differences were
also noted. The hierarchical clustering analysis indicated
that the multiple foci may not have arisen due to the
clonal metastasis of tumour cells or of independently
mutational events, but perhaps both phenomena can
occur simultaneously within the one tumour to enhance
cancer progression.
This study illustrates the potential variability of miRNA
expression in different tumour micro-environments. It
highlights the importance of considering and reporting
the areas of the tumour from which cells are excised for
the study of miRNA expression. In light of this informa-
tion, studies reporting miRNA signatures specific for dis-
ease types may need to be refined to allow for or exploit
this variability. Studies may choose to report global
expression patterns for whole sections of tumour, or alter-
natively focus on miRNA patterns that associate with pro-
pensity for metastasis – e.g. miRNAs altered in vascular
areas, or perhaps those miRNAs with altered expression in
hypoxic areas of tumour – which might correlate with
resistance to chemotherapeutic intervention. The latter
approach has particular promise in a translational medi-
cine setting where a personalised approach to medicine
may be indicated.
Another approach might be to investigate the differen-
tially regulated miRNAs harvested from nominated areas
(e.g. areas exhibiting lymphocytic infiltration or vascular
invasion) of different types of tumours to determine
whether they are universal markers of these features, or
specific to lymphocytic infiltration or increased vasculari-
sation in the thyroid.
Finally, when considering the best potential applications
of miRNAs, either as biomarkers or biological mediators
of disease, the answer remains to be seen. Further research
is required to provide both solid information on the gene
targets of these RNAs and robust miRNA biomarker signa-
tures.
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